Subtype
Urinary Tract Neoplasm
CI-CAN-00001627Explore in graph →
Non-malignant558 active trials14 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001627Explore in graph →
Clinical trials
2,187 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07420517 | Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer(DutaBCa-1) | recruiting | Phase 2 | 95 | Paul TorenOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06800963 | ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG | recruiting | Phase 1 / Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07495072 | Early vs Delayed Intravesical Blad-Care During BCG Therapy(PRO-GAG) | recruiting | N/A | 56 | BLAD-HYA GroupOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06447064 | Cancer Loyalty Card Study 2 (CLOCS-2)((CLOCS-2)) | recruiting | — | 2,900 | Imperial College LondonOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07481851 | Skin Conductance for Predicting Spinal Anesthesia-Induced Hypotension in Geriatric Urologic Oncology Patients | recruiting | — | 102 | Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07492628 | Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma(DUET-UC-NK) | recruiting | Phase 1 | 42 | Beijing BiotechINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05037279 | Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)(EVER) | recruiting | Phase 3 | 540 | Verity Pharmaceuticals Inc.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06721260 | Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)(METRICS) | recruiting | — | 30 | University of Kansas Medical CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04970472 | Bio Clinical Collection of Urothelial Carcinoma(MicroBlad) | recruiting | — | 1,000 | University Hospital, ToulouseOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05888532 | 64Cu-GRIP B in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 91 | Rahul AggarwalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05102110 | Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.(ORI-EGI-03) | recruiting | — | 450 | Origin SciencesINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06109857 | Bladder Bank (a Prospective Banking Study) | recruiting | — | 1,500 | Mayo ClinicOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07474519 | Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer | recruiting | Phase 4 | 40 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06173349 | PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer | recruiting | Phase 1 | 12 | University of California, DavisOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07050771 | Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery | recruiting | Phase 2 | 148 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06488222 | Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer | recruiting | Phase 2 | 34 | University of FloridaOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT03413982 | Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers(GUB-BCR-001) | recruiting | — | 1,000 | University of Kansas Medical CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04075305 | The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study(MOMENTUM) | recruiting | — | 8,000 | UMC UtrechtOTHER | 9 | Mar 5, 2026 | clinicaltrials |
| NCT06528990 | Telehealth Intervention for Ostomy Self-Management | recruiting | Phase 2 | 150 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07452432 | Korean Prospective Upper Tract Urothelial Carcinoma Cohort | recruiting | — | 300 | Samsung Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05321316 | Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma | recruiting | N/A | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07088536 | Occupational Situation and Return to Work of Urological Patients(OCCURORTW) | recruiting | — | 2,000 | Jagiellonian UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07130578 | The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer | recruiting | — | 60 | Tianjin Medical University Second HospitalOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07441499 | Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma | recruiting | — | 300 | Tianjin Medical University Second HospitalOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05679557 | Comprehensive Geriatric Assessment for Perioperative Optimization in Cystectomy(COMPETENCE) | recruiting | N/A | 140 | Aarhus University HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07424560 | Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer | recruiting | — | 400 | Zhilong DongOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07221942 | Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma(IMPROEV) | recruiting | Phase 2 | 97 | Fox Chase Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06470282 | Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 47 | University of California, San FranciscoOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06138561 | Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments | recruiting | — | 180 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07234968 | Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy | recruiting | N/A | 70 | Thomas Jefferson UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07403630 | INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)(IT-TCP POS) | recruiting | N/A | 300 | Azienda Ospedaliero-Universitaria di ParmaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06764095 | Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial | recruiting | Phase 4 | 75 | Mayo ClinicOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04368702 | CONFIRM: Magnetic Resonance Guided Radiation Therapy(CONFIRM) | recruiting | N/A | 70 | Brigham and Women's HospitalOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07395037 | A Study of Ward Admissions for Haematuria(WASHOUT) | recruiting | — | 1,050 | British Urology Researchers in Surgical TrainingOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT03740256 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors(VISTA) | recruiting | Phase 1 | 45 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04916990 | Improving Care for Rural Patients With Solid Tumors | recruiting | N/A | 320 | University of Colorado, DenverOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06349668 | Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery(SMILe) | recruiting | Phase 3 | 220 | Hans BahlmannOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03193515 | A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer | recruiting | — | 300 | Cedars-Sinai Medical CenterOTHER | 2 | Feb 4, 2026 | clinicaltrials |
| NCT03193541 | A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer | recruiting | — | 900 | Cedars-Sinai Medical CenterOTHER | 2 | Feb 4, 2026 | clinicaltrials |
| NCT07183319 | Circulating Tumor DNA Response In Urothelial Cancer | recruiting | Phase 2 | 30 | University of OklahomaOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07379255 | Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology. | recruiting | — | 266 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07379268 | Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology. | recruiting | — | 224 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07379281 | Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology | recruiting | — | 254 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04623502 | An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy | recruiting | N/A | 600 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06818136 | Bladder EpiCheck European Haematuria Study | recruiting | — | 800 | Nucleix Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07359235 | Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC) | recruiting | Phase 1 | 29 | Tongji HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 30, 2026source: clinicaltrials